A1AQX
Camlipixant
| Created: | 2024-05-08 |
| Last modified: | 2025-03-19 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 57 |
| Chiral Atom Count | 1 |
| Bond Count | 60 |
| Aromatic Bond Count | 16 |
Chemical Component Summary | |
|---|---|
| Name | Camlipixant |
| Systematic Name (OpenEye OEToolkits) | methyl (2~{S})-2-[[2-[2,6-bis(fluoranyl)-4-(methylcarbamoyl)phenyl]-7-methyl-imidazo[1,2-a]pyridin-3-yl]methyl]morpholine-4-carboxylate |
| Formula | C23 H24 F2 N4 O4 |
| Molecular Weight | 458.458 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | ACDLabs | 12.01 | COC(=O)N1CC(Cc2c(nc3cc(C)ccn32)c2c(F)cc(cc2F)C(=O)NC)OCC1 |
| SMILES | CACTVS | 3.385 | CNC(=O)c1cc(F)c(c(F)c1)c2nc3cc(C)ccn3c2C[CH]4CN(CCO4)C(=O)OC |
| SMILES | OpenEye OEToolkits | 2.0.7 | Cc1ccn2c(c1)nc(c2CC3CN(CCO3)C(=O)OC)c4c(cc(cc4F)C(=O)NC)F |
| Canonical SMILES | CACTVS | 3.385 | CNC(=O)c1cc(F)c(c(F)c1)c2nc3cc(C)ccn3c2C[C@H]4CN(CCO4)C(=O)OC |
| Canonical SMILES | OpenEye OEToolkits | 2.0.7 | Cc1ccn2c(c1)nc(c2C[C@H]3CN(CCO3)C(=O)OC)c4c(cc(cc4F)C(=O)NC)F |
| InChI | InChI | 1.06 | InChI=1S/C23H24F2N4O4/c1-13-4-5-29-18(11-15-12-28(6-7-33-15)23(31)32-3)21(27-19(29)8-13)20-16(24)9-14(10-17(20)25)22(30)26-2/h4-5,8-10,15H,6-7,11-12H2,1-3H3,(H,26,30)/t15-/m0/s1 |
| InChIKey | InChI | 1.06 | SEHLMRJSQFAPCJ-HNNXBMFYSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB19217 |
|---|---|
| Name | Camlipixant |
| Groups | investigational |
| Description | Camlipixant is under investigation in clinical trial NCT05600777 (A 24-week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)). |
| Synonyms |
|
| CAS number | 1621164-74-6 |
Related Resource References
| Resource Name | Reference |
|---|---|
| PubChem | 76955630 |
| ChEMBL | CHEMBL5095035 |














